SEARCH

SEARCH BY CITATION

References

  • 1
    Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994; 107: 10319.
  • 2
    Ghosh S. Osteopenia. In: Jewell, DP, Warren, BF, Mortensen, NJ, eds. Challenges in Inflammatory Bowel Disease. London: Blackwell Science, 2001: 25066.
  • 3
    Compston JE. Review article: Osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther 1995; 9: 23750.
  • 4
    Compston JE. Osteoporosis in inflammatory bowel disease. Gut 2003; 52: 634.
  • 5
    Bernstein CN, Leslie D, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124: 795841.
  • 6
    Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease. A population-based cohort study. Ann Intern Med 2000; 133: 7959.
  • 7
    Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001; 48: 4737.
  • 8
    Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 1995; 10: 2506.
  • 9
    Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997; 99: 1699703.
  • 10
    Bickel M, Axtelius B, Solioz C, Attstrom R. Cytokine gene expression in chronic periodontitis. J Clin Periodontol 2001; 28: 8407.
  • 11
    Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res 2002; 4: 2819.
  • 12
    Origuchi T, Migita K, Nakashima T, et al. IL-1-mediated expression of membrane type matrix-metalloproteinase in rheumatoid osteoblasts. Clin Exp Rheumatol 2000; 18: 3339.
  • 13
    Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 8417.
  • 14
    Matsuno H, Yudoh K, Katayama R, et al. The role of TNF-alpha in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford) 2002; 41: 32937.
  • 15
    Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 1991; 32: 9137.
  • 16
    Komatsu M, Kobayashi D, Saito K, et al. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem 2001; 47: 1297301.
  • 17
    Lanfranchi GA, Tragnone A. Serum and faecal tumour necrosis factor-alpha as marker of intestinal inflammation. Lancet 1992; 339(8800): 1053.
  • 18
    Martinez-Borra J, Lopez-Larrea C, Gonzalez S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol 2002; 97: 23506.
  • 19
    Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 2001; 187: 294303.
  • 20
    Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002; 17: 695702.
  • 21
    Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001; 276: 5638.
  • 22
    Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 14818.
  • 23
    Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001; 83: 7083.
  • 24
    Fuller K, Murphy C, Kirstein B, Fox SW, Chambers TJ. TNF alpha potently activates osteoclasts, through a direct action independent of and strongly synergistic with RANKL. Endocrinology 2002; 143: 110818.
  • 25
    Lee SE, Chung WJ, Kwak HB, et al. Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK. J Biol Chem 2001; 276: 493439.
  • 26
    Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141: 395664.
  • 27
    Taichman RS, Hauschka PV. Effects of interleukin-1 beta and tumor necrosis factor-alpha on osteoblastic expression of osteocalcin and mineralized extracellular matrix in vitro. Inflammation 1992; 16: 587601.
  • 28
    Looker AC, Bauer DC, Chesnut CH III, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000; 11: 46780.
  • 29
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998; 13: 14318.
  • 30
    Greenspan SL, Rosen HN, Parker RA. Early changes in serum N-telopeptide and C-telopeptide cross-linked collagen type 1 predict long-term response to alendronate therapy in elderly women. J Clin Endocrinol Metab 2000; 85: 353740.
  • 31
    Compston JE. Can biochemical markers be used to screen patients with inflammatory bowel disease for osteoporosis? Eur J Gastroenterol Hepatol 2002; 14: 5879.
  • 32
    Bregenzer N, Erban P, Albrich H, et al. Screening for osteoporosis in patients with inflammatory bowel disease by using urinary N-telopeptides. Eur J Gastroenterol Hepatol 2002; 14: 599605.
  • 33
    Robinson RJ, Iqbal SJ, Wolfe R, Patel K, Abrams K, Mayberry JF. The effect of rectally administered steroids on bone turnover: a comparative study. Aliment Pharmacol Ther 1998; 12: 2137.
  • 34
    Schoon EJ, Geerling BG, Van Dooren IM, et al. Abnormal bone turnover in long-standing Crohn's disease in remission. Aliment Pharmacol Ther 2001; 15: 78392.
  • 35
    Baert FJ, D'Haens G, Peeters M, et al. Tumor necrosis factor alpha (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999; 116: 228.
  • 36
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 37
    Lennard-Jones J. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(Suppl. 170): 26.
  • 38
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 39
    Putzeys V, Franchimont N, Vermeire S, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Gut 2003; 52(Suppl. 1): A45.
  • 40
    Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002; 12: 1895902.
  • 41
    Robinson RJ, Iqbal SJ, Abrams K, Al-Azzawi F, Mayberry JF. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12: 699705.
  • 42
    Bischoff SC, Herrmann A, Goke M, Manns MP, Zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997; 92: 115763.
  • 43
    Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996; 111: 126371.
  • 44
    Varghese S, Wyzga N, Griffiths AM, Sylvester FA. Effects of serum from children with newly diagnosed Crohn's disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 2002; 35: 6418.
  • 45
    Hyams JS, Wyzga N, Kreutzer DL, Justinich CJ, Gronowicz GA. Alterations in bone metabolism in children with inflammatory bowel disease: an in vitro study. J Pediatr Gastroenterol Nutr 1997; 24: 28995.
  • 46
    Abu-Amer Y, Erdmann J, Alexopoulou L, Kollias G, Ross FP, Teitelbaum SL. Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000; 275: 2730710.
  • 47
    Van Den Brande JM, Braat H, Van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 177485.
  • 48
    Van Den Brande JM, Peppelenbosch MP, Van Deventer SJ. Treating Crohn's disease by inducing T lymphocyte apoptosis. Ann N Y Acad Sci 2002; 973: 16680.
  • 49
    Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 50
    Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999; 163: 15218.
  • 51
    Allali F, Breban M, Porcher R, Maillefort JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 2003; 62: 3479.